NLS Pharmaceutics Valuation
| NLSP Stock | USD 1.51 0.01 0.67% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. NLS Pharmaceutics secures a last-minute Real Value of $1.45 per share. The latest price of the firm is $1.51. Our model forecasts the value of NLS Pharmaceutics from inspecting the firm fundamentals such as Current Valuation of 7.29 M, return on equity of -8.63, and Return On Asset of -2.28 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting NLS Pharmaceutics' valuation include:
Overvalued
Today
Please note that NLS Pharmaceutics' price fluctuation is abnormally volatile at this time. Calculation of the real value of NLS Pharmaceutics is based on 3 months time horizon. Increasing NLS Pharmaceutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
NLS Pharmaceutics' intrinsic value may or may not be the same as its current market price of 1.51, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.51 | Real 1.45 | Target 6.0 | Hype 1.51 | Naive 1.83 |
The intrinsic value of NLS Pharmaceutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NLS Pharmaceutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NLS Pharmaceutics AG helps investors to forecast how NLS stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NLS Pharmaceutics more accurately as focusing exclusively on NLS Pharmaceutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use NLS Pharmaceutics' intrinsic value based on its ongoing forecasts of NLS Pharmaceutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against NLS Pharmaceutics' closest peers.
NLS Pharmaceutics Cash |
|
NLS Valuation Trend
NLS Pharmaceutics' real value is important for investors to make better decisions and a more accurate overall view of NLS Pharmaceutics' financial worth over time. Using both NLS Pharmaceutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
NLS Pharmaceutics Total Value Analysis
NLS Pharmaceutics AG is now projected to have valuation of 7.29 M with market capitalization of 6.13 M, debt of 1.63 M, and cash on hands of 1.35 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the NLS Pharmaceutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
7.29 M | 6.13 M | 1.63 M | 1.35 M |
NLS Pharmaceutics Asset Utilization
One of the ways to look at asset utilization of NLS is to check how much profit was generated for every dollar of assets it reports. NLS Pharmaceutics AG secures a negative usage of assets of -2.28 %, losing $0.0228 for each dollar of assets held by the firm. Unsuccessful asset utilization conveys that the company is being less competent with each dollar of assets it secures. Strictly speaking, asset utilization of NLS Pharmaceutics AG shows how unproductive it operates for each dollar spent on its assets.NLS Pharmaceutics Ownership Allocation
NLS Pharmaceutics AG holds noticeable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.NLS Pharmaceutics Profitability Analysis
Net Loss for the year was (12.17 M) with profit before overhead, payroll, taxes, and interest of 0.About NLS Pharmaceutics Valuation
The stock valuation mechanism determines NLS Pharmaceutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of NLS Pharmaceutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of NLS Pharmaceutics. We calculate exposure to NLS Pharmaceutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NLS Pharmaceutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -10.3 K | -10.8 K |
NLS Pharmaceutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as NLS Pharmaceutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 38.2 M |
NLS Pharmaceutics Current Valuation Indicators
NLS Pharmaceutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final NLS Pharmaceutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as NLS Pharmaceutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use NLS Pharmaceutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes NLS Pharmaceutics' worth.Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.